UniProtKB/Swiss-Prot P00441: Variant p.Gly94Asp

• Variant information
• Sequence information
• Literature citations
• All

Variant information

Variant position: 94 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Type of variant: LP/P [Disclaimer: Variants classification is intended for research purposes only, not for clinical and diagnostic use. The label disease variant is assigned according to literature reports on probable disease-association that can be based on theoretical reasons. This label must not be considered as a definitive proof for the pathogenic role of a variant.] The variants are classified into three categories: LP/P, LB/B and US.

• LP/P: likely pathogenic or pathogenic.
• LB/B: likely benign or benign.
• US: uncertain significance

Residue change: From Glycine (G) to Aspartate (D) at position 94 (G94D, p.Gly94Asp). Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.
Physico-chemical properties: Change from glycine (G) to medium size and acidic (D) The physico-chemical property of the reference and variant residues and the change implicated.
BLOSUM score: -1 The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:

• Lowest score: -4 (low probability of substitution).
• Highest score: 11 (high probability of substitution).

More information can be found on the following page
Variant description: In ALS1. Any additional useful information about the variant.
Other resources: Links to websites of interest for the variant.

• Variant rs121912438 [ dbSNP | Ensembl ]

Sequence information

Variant position: 94 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length: 154 The length of the canonical sequence.
Location on the sequence: GPKDEERHVGDLGNVTADKD G VADVSIEDSVISLSGDHCII The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Sequence annotation in neighborhood: The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:

• Type: the type of sequence feature.
• Positions: endpoints of the sequence feature.
• Description: contains additional information about the feature.

Type	Positions	Description
Chain	2 – 154	Superoxide dismutase [Cu-Zn]
Binding site	81 – 81
Binding site	84 – 84
Modified residue	92 – 92	N6-succinyllysine
Modified residue	99 – 99	Phosphoserine
Modified residue	103 – 103	Phosphoserine
Modified residue	106 – 106	Phosphoserine
Modified residue	108 – 108	Phosphoserine
Disulfide bond	58 – 147
Mutagenesis	81 – 81	H -> A. Loss of zinc binding and enhanced tendency to form aggregates; when associated with A-84.
Mutagenesis	81 – 81	H -> S. Destabilization of dimer and loss of zinc binding; when associated with S-84.
Mutagenesis	84 – 84	D -> A. Loss of zinc binding and enhanced tendency to form aggregates; when associated with A-81.
Mutagenesis	84 – 84	D -> S. Destabilization of dimer and loss of zinc binding; when associated with S-81.
Mutagenesis	112 – 112	C -> S. Enhances formation of fibrillar aggregates in the absence of bound zinc; when associated with S-7; S-58 and S-147.
Helix	92 – 94

Literature citations

Identification of two novel mutations and a new polymorphism in the gene for Cu/Zn superoxide dismutase in patients with amyotrophic lateral sclerosis.
Esteban J.; Rosen D.R.; Bowling A.C.; Sapp P.; McKenna-Yasek D.; O'Regan J.P.; Beal M.F.; Horvitz H.R.; Brown R.H. Jr.;
Hum. Mol. Genet. 3:997-998(1994)
Cited for: VARIANTS ALS1 ASP-94 AND THR-113; SOD1 and amyotrophic lateral sclerosis: mutations and oligomerization.
Banci L.; Bertini I.; Boca M.; Girotto S.; Martinelli M.; Valentine J.S.; Vieru M.;
PLoS ONE 3:E1677-E1677(2008)
Cited for: CHARACTERIZATION OF VARIANTS ALS1 ARG-55; ALA-91; ALA-94; ASP-94; MET-98 AND PHE-145;